CLS

Celestica Announces Pricing of Secondary Offering of Subordinate Voting Shares by Onex Corporation

Retrieved on: 
Tuesday, June 6, 2023

Celestica is not selling any shares and will not receive any proceeds from the offering.

Key Points: 
  • Celestica is not selling any shares and will not receive any proceeds from the offering.
  • RBC Capital Markets is acting as the underwriter for the offering.
  • The offering is expected to close on June 8, 2023, subject to the satisfaction of customary closing conditions.
  • Any public offering of securities in the United States or Canada will be made solely by means of ‎the applicable prospectus and prospectus supplement.

The Institute for Functional Medicine Celebrates Scholarship and Linus Pauling Award Winners at the 30th Annual International Conference

Retrieved on: 
Tuesday, June 6, 2023

FEDERAL WAY, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- The Institute for Functional Medicine (IFM) is delighted to announce the winners of its prestigious Linus Pauling Award in Functional Medicine, Debbie Sanstad Memorial Scholarship, and the inaugural Founders’ Scholarships, presented at the highly anticipated 2023 Annual International Conference (AIC).

Key Points: 
  • FEDERAL WAY, Wash., June 06, 2023 (GLOBE NEWSWIRE) -- The Institute for Functional Medicine (IFM) is delighted to announce the winners of its prestigious Linus Pauling Award in Functional Medicine, Debbie Sanstad Memorial Scholarship, and the inaugural Founders’ Scholarships, presented at the highly anticipated 2023 Annual International Conference (AIC).
  • The 2023 Linus Pauling Award recognizes Aristo Vojdani, PhD, MSc, CLS for his exceptional work as a scholar, researcher, and teacher.
  • IFM is proud to offer annual scholarships to expand access to functional medicine training for practitioners.
  • The achievements of IFM scholarship award recipients and contributions of the Linus Pauling Award in Functional Medicine winners support IFM’s efforts to improve the quality of care for all populations, lower financial barriers to functional medicine care and training, and integrate functional medicine into more clinics, health systems, and academic medicine settings.

Celestica Announces Proposed Secondary Offering of Subordinate Voting Shares by Onex Corporation

Retrieved on: 
Monday, June 5, 2023

Celestica is not selling any shares and will not receive any proceeds from the proposed offering.

Key Points: 
  • Celestica is not selling any shares and will not receive any proceeds from the proposed offering.
  • RBC Capital Markets will act as the underwriter for the proposed offering.
  • Prospective investors in the United States should read the base prospectus, registration statement, the prospectus supplement related to this offering and the documents incorporated by reference therein.
  • Any public offering of securities in the United States or Canada will be made solely by means of ‎the applicable prospectus and prospectus supplement.

CLS Americas Announces the National Institutes of Health Clinical Center Placed its 1st Order of the TRANBERG™ Thermal Therapy System for its Research Study - MRI/Ultrasound Fusion-Guided FLA of Prostate Tissue and Prostate Cancer

Retrieved on: 
Thursday, June 1, 2023

The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.

Key Points: 
  • The order falls under the previously announced research collaboration agreement between NIHCC and its parent company, Clinical Laserthermia Systems AB, based in Sweden.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “CLS is pleased to begin this collaboration with the NIH to evaluate our TRANBERG laser for image-guided, focal therapies to treat prostate cancer,” said Michael Magnani, President of CLS Americas.
  • A TRANBE RG FLA Animation Video of the system and procedure is available to watch.

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

Retrieved on: 
Thursday, June 1, 2023

ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD).

Key Points: 
  • ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that enrollment has opened in ODYSSEY, its Phase 2b clinical trial of CLS-AX (axitinib injectable suspension) using suprachoroidal delivery in neovascular age-related macular degeneration (wet AMD).
  • “With the ODYSSEY clinical trial now open for enrollment, we are excited to continue exploring the potential of CLS-AX to provide an effective and less burdensome treatment option in the multi-billion-dollar wet AMD market,” said George Lasezkay, Pharm.D., J.D., Clearside’s President and Chief Executive Officer.
  • We believe that the number of participants, duration, and outcome measures of the study will provide the necessary clinical data to design a CLS-AX Phase 3 program.
  • We are targeting a total of 30 U.S. based clinical trial sites for ODYSSEY and expect to report topline data from the trial in the third quarter of next year,” concluded Dr. Lasezkay.

Announcing 2023 F&L Asia Awards Winners

Retrieved on: 
Thursday, June 1, 2023

Since 2017, F+L Week has honoured outstanding individuals and groundbreaking products with the prestigious F&L Asia Awards.

Key Points: 
  • Since 2017, F+L Week has honoured outstanding individuals and groundbreaking products with the prestigious F&L Asia Awards.
  • View the full release here: https://www.businesswire.com/news/home/20230601005551/en/
    F&L Asia Person of the Year for 2023 Goh Koon Eng (Photo: Business Wire)
    We are proud to announce Goh Koon Eng of Chevron Oronite as the F&L Asia Person of the Year for 2023.
  • F&L Asia is excited to announce Russell as the recipient of the F&L Asia Lifetime Achievement Award for 2023.
  • Dr. Wenyang Zhang, senior staff mechanical design engineer at Tesla, Inc., is honoured with the F&L Asia Future Leaders Award for 2023.

REVISED - CLS Americas Announces AVANT Concierge Urology has Treated its First Prostate Cancer Patients using the TRANBERG™ Thermal Therapy System

Retrieved on: 
Tuesday, May 16, 2023

Under a Mobile Services Provider (MSP) Agreement, CLS has provided its 510(k) cleared, TRANBERG Thermal Therapy System as a rental, with consumable accessories, training, and on-site clinical and technical staff support to AVANT physicians and staff during procedures.

Key Points: 
  • Under a Mobile Services Provider (MSP) Agreement, CLS has provided its 510(k) cleared, TRANBERG Thermal Therapy System as a rental, with consumable accessories, training, and on-site clinical and technical staff support to AVANT physicians and staff during procedures.
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We are pleased to see Dr. Parekattil treating his low-to-intermediate risk prostate cancer patients utilizing our minimally invasive TRANBERG Thermal Therapy System,” stated Michael Magnani, president of CLS Americas.
  • Patients usually have only minor pain and recover quickly.”
    The TRANBERG Thermal Therapy System can be configured for MR/US fusion-guided procedures using real-time tissue temperature measurements for precise therapy and ablation control.

Orchest Selects NJFX Connectivity Hub for Unique Offerings

Retrieved on: 
Thursday, May 11, 2023

WESTON, Fla., May 11, 2023 /PRNewswire/ -- Orchest Technologies, a leading provider of wholesale connectivity solutions and pioneer of network automation in Latin America, is now offering pay-as-you-go services out of NJFX's carrier-neutral CLS campus in Wall Township, New Jersey. This move provides businesses with the flexibility to connect to the right network operator while avoiding legacy congestion points, such as Miami and New York.

Key Points: 
  • Networks can scale their connectivity needs according to their budget, without having to worry about overpaying for unused resources.
  • "On-Demand connectivity opens incredible possibilities for different verticals or even carriers looking to expand into Latam while minimizing risk and cost of entry.
  • This direct access to global connectivity provides businesses with the ability to expand their reach and enhance their presence.
  • "Utilizing the Seabras-1 cable at NJFX, plus access to the other LATAM Subsea cables, via our 35 network operators creates diverse network connectivity and diversity from Miami," said Gil Santaliz, CEO at NJFX.

CLS Americas Announces AVANT Concierge Urology has Treated its First Prostate Cancer Patients using the TRANBERG™ Thermal Therapy System

Retrieved on: 
Thursday, May 11, 2023

IRVINE, Calif. and ORLANDO, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that AVANT Concierge Urology of Winterhaven, FL, has safely treated its first patients with low-to- intermediate risk prostate cancer using its TRANBERG™ Thermal Therapy System .

Key Points: 
  • IRVINE, Calif. and ORLANDO, Fla., May 11, 2023 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems Americas, Inc. (CLS), a leading provider of office-based, focal laser ablation (FLA) systems for urologists, today announced that AVANT Concierge Urology of Winterhaven, FL, has safely treated its first patients with low-to- intermediate risk prostate cancer using its TRANBERG™ Thermal Therapy System .
  • In the US, over one million prostate biopsies are performed every year leading to a diagnosis of prostate cancer for almost 250,000 men.
  • “We are pleased to see Dr. Parekattil treating his low-to-intermediate risk prostate cancer patients utilizing our minimally invasive TRANBERG Thermal Therapy System,” stated Michael Magnani, president of CLS Americas.
  • Patients usually have only minor pain and recover quickly.”
    The TRANBERG Thermal Therapy System can be configured for MR/US fusion-guided procedures using real-time tissue temperature measurements for precise therapy and ablation control.

Celestica Announces Election of Directors

Retrieved on: 
Thursday, April 27, 2023

TORONTO, April 27, 2023 (GLOBE NEWSWIRE) -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced, in accordance with the requirements of the Toronto Stock Exchange, that the nominees listed in its management information circular were elected as directors of the company at its Annual Meeting of Shareholders held earlier today.

Key Points: 
  • TORONTO, April 27, 2023 (GLOBE NEWSWIRE) -- Celestica Inc. (NYSE, TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced, in accordance with the requirements of the Toronto Stock Exchange, that the nominees listed in its management information circular were elected as directors of the company at its Annual Meeting of Shareholders held earlier today.
  • On a vote by ballot, each of the following ten nominees proposed by management was elected as a director of Celestica: